Windlas Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Windlas Biotech reported consolidated FY25 revenue from operations of Rs. 7,598.78 million, up about 20.4% from Rs. 6,309.56 million in FY24. Profit for the year grew modestly to Rs. 609.94 million (from Rs. 581.87 million, ~4.8% rise), while basic EPS improved to Rs. 29.19 vs Rs. 27.97. Q4 standalone revenue came in at Rs. 2,027.05 million, and the board has recommended a dividend of Rs. 5.80 per share (116% on face value of Rs. 5). The joint venture USpharma Windlas LLC ceased to exist from July 12, 2024. The statutory auditors S S Kothari Mehta & Co. LLP issued an unmodified opinion on both standalone and consolidated results.
Strong top-line growth of over 20% signals healthy business expansion, though muted profit growth (~5%) and a sharp drop in operating cash flow (Rs. 681.87M vs Rs. 1,089.60M) may temper investor enthusiasm. The Rs. 5.80 dividend and new ESOP plan are positive shareholder-friendly actions.